Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15610318 | 1.00 | ALOX5 (0.48) | ALOX5ALDH1A1CRBNCA2CA1 | |
| SCHEMBL15610560 | 1.00 | ALOX5 (0.48) | ALOX5ALDH1A1CRBNCA2CA1 | |
| SCHEMBL7970254 | 0.86 | ALOX5 (0.64) | ALOX5ALDH1A1CRBNGAAHDAC1 | |
| SCHEMBL15631042 | 0.83 | ALOX5 (0.49) | ALOX5ALDH1A1CRBNCA2CA1 | |
| SCHEMBL15631043 | 0.83 | ALOX5 (0.49) | ALOX5ALDH1A1CRBNCA2CA1 | |
| SCHEMBL1949865 | 0.79 | ALOX5AP (0.50) | — | |
| SCHEMBL4509415 | 0.78 | POLB (0.60) | ALDH1A1LMNASMN1; SMN2CCKARPOLB | |
| SCHEMBL15610140 | 0.77 | MAPT (0.48) | ALDH1A1LMNASMN1; SMN2POLBMAPT | |
| SCHEMBL15610146 | 0.77 | MAPT (0.48) | ALDH1A1LMNASMN1; SMN2POLBMAPT | |
| SCHEMBL15610141 | 0.77 | MAPT (0.48) | ALDH1A1LMNASMN1; SMN2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900629-A2 | F-18 RADIOLABELED COMPOUNDS FOR DIAGNOSING AND MONITORING KIDNEY FUNCTION | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2015-08-05 | — | — | EP | disclosed |
| CN-104703963-A | F-18 radiolabeled compounds for diagnosing and monitoring kidney function | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD | 2015-06-10 | — | — | CN | disclosed |
| US-8906344-B2 | F-18 radiolabeled compounds for diagnosing and monitoring kidney function | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-20140086837-A1 | F-18 RADIOLABELED COMPOUNDS FOR DIAGNOSING AND MONITORING KIDNEY FUNCTION | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2014-03-27 | — | — | US | disclosed |
| WO-2014045306-A2 | F-18 RADIOLABELED COMPOUNDS FOR DIAGNOSING AND MONITORING KIDNEY FUNCTION | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2014-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140086837-A1 | F-18 RADIOLABELED COMPOUNDS FOR DIAGNOSING AND MONITORING KIDNEY FUNCTION | SLCO1B1, SLCO1B3, SLCO2B1 | ALOX5 3932/4885ALDH1A1 671/4885CRBN 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.